

CITATION REPORT

List of articles citing

Hydroxychloroquine-induced restrictive cardiomyopathy

DOI: 10.1016/j.euje.2006.02.002

European Journal of Echocardiography, 2007, 8, 247-51.

Source: <https://exaly.com/paper-pdf/41507285/citation-report.pdf>

Version: 2024-04-23

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
40	New clinical and ultrastructural findings in hydroxychloroquine-induced cardiomyopathy--a report of 2 cases. <i>Human Pathology</i> , 2007 , 38, 1858-63	3.7	49
39	Current awareness: Pharmacoepidemiology and drug safety. <i>Pharmacoepidemiology and Drug Safety</i> , 2008 , 17, i-xii	2.6	
38	Cardiotoxicity after low-dose chloroquine antimalarial therapy. <i>Heart and Vessels</i> , 2009 , 24, 385-7	2.1	14
37	[Chloroquine cardiotoxicity in long-term lupus therapy in two patients]. <i>Annales De Dermatologie Et De Venereologie</i> , 2009 , 136, 530-5	0.3	12
36	Antiprotozoal drugs. <i>Side Effects of Drugs Annual</i> , 2010 , 521-528	0.2	
35	Case records of the Massachusetts General Hospital. Case 11-2011. A 47-year-old man with systemic lupus erythematosus and heart failure. <i>New England Journal of Medicine</i> , 2011 , 364, 1450-60	59.2	34
34	Cardiomyopathy caused by longterm treatment with chloroquine: a rare disease, or a rare diagnosis?. <i>Journal of Rheumatology</i> , 2012 , 39, 1099-103	4.1	20
33	Fatal antimalarial-induced cardiomyopathy: report of 2 cases. <i>Journal of Clinical Rheumatology</i> , 2012 , 18, 363-6	1.1	23
32	Evidence for risk of cardiomyopathy with hydroxychloroquine. <i>Lupus</i> , 2012 , 21, 1594-6	2.6	22
31	Lipid paradox in rheumatoid arthritis: changes with rheumatoid arthritis therapies. <i>Current Rheumatology Reports</i> , 2012 , 14, 428-37	4.9	29
30	Hydroxychloroquine-induced cardiomyopathy that presented as pulmonary hypertension: a newly noted complication. <i>Cardiology</i> , 2012 , 123, 197-200	1.6	9
29	Cardiac Involvement. 2012 , 373-393		1
28	Chloroquine cardiomyopathy - a review of the literature. <i>Immunopharmacology and Immunotoxicology</i> , 2013 , 35, 434-42	3.2	120
27	Hydroxychloroquine cardiotoxicity presenting as a rapidly evolving biventricular cardiomyopathy: key diagnostic features and literature review. <i>European Heart Journal: Acute Cardiovascular Care</i> , 2013 , 2, 77-83	4.3	92
26	Rheumatoid arthritis and cardiac disease. <i>International Journal of Clinical Rheumatology</i> , 2014 , 9, 457-473.5		
25	Cardiovascular disease in rheumatoid arthritis. <i>Rheumatic Disease Clinics of North America</i> , 2014 , 40, 27-49.4	2.4	27
24	Three Cases of Fatal Lupus Cardiomyopathy: Clinical Features and Outcomes. <i>Journal of Clinical Rheumatology</i> , 2015 , 21, 379-81	1.1	1

23	Chloroquine and hydroxychloroquine. 2016 , 253-267		1
22	Constrictive Pericarditis Versus Restrictive[Cardiomyopathy?. <i>Journal of the American College of Cardiology</i> , 2016 , 67, 2061-76	15.1	58
21	Restrictive Cardiomyopathy Associated With Long-Term Use of Hydroxychloroquine for Systemic Lupus Erythematosus. <i>Journal of Pharmacy Practice</i> , 2017 , 30, 571-575	1.3	4
20	Antimalarial-induced cardiomyopathy: a systematic review of the literature. <i>Lupus</i> , 2018 , 27, 591-599	2.6	32
19	Cardiac Complications Attributed to Chloroquine and Hydroxychloroquine: A Systematic Review of the Literature. <i>Drug Safety</i> , 2018 , 41, 919-931	5.1	195
18	Current and Future Use of Chloroquine and Hydroxychloroquine in Infectious, Immune, Neoplastic, and Neurological Diseases: A Mini-Review. <i>Clinical Drug Investigation</i> , 2018 , 38, 653-671	3.2	152
17	Hypertrophic cardiomyopathy in a lupus patient: a case of hydroxychloroquine cardiotoxicity. <i>ESC Heart Failure</i> , 2019 , 6, 1326-1330	3.7	5
16	A Case of Cardiomyopathy With Long-term Hydroxychloroquine Use. <i>Journal of Clinical Rheumatology</i> , 2020 , 26, e300	1.1	
15	Therapeutic use of chloroquine and hydroxychloroquine in COVID-19 and other viral infections: A narrative review. <i>Travel Medicine and Infectious Disease</i> , 2020 , 35, 101735	8.4	71
14	Hydroxychloroquine: a comprehensive review and its controversial role in coronavirus disease 2019. <i>Annals of Medicine</i> , 2021 , 53, 117-134	1.5	26
13	COVID-19. 2021 , 203-210		
12	[Toxic hydroxychloroquine-induced cardiomyopathy complicating systemic lupus treatment]. <i>Annales De Pathologie</i> , 2021 , 41, 101-104	0.3	0
11	Effects of Chloroquine and Hydroxychloroquine on the Cardiovascular System - Limitations for Use in the Treatment of COVID-19. <i>International Journal of Cardiovascular Sciences</i> , 2021 ,	0.4	1
10	A large-scale computational screen identifies strong potential inhibitors for disrupting SARS-CoV-2 S-protein and human ACE2 interaction. <i>Journal of Biomolecular Structure and Dynamics</i> , 2021 , 1-14	3.6	0
9	Cardiac Complications Attributed to Hydroxychloroquine: A Systematic Review of the Literature Pre-COVID-19. <i>Current Cardiology Reviews</i> , 2021 , 17, 319-327	2.4	2
8	Heart failure associated with imported malaria: a nationwide Danish cohort study. <i>ESC Heart Failure</i> , 2021 , 8, 3521-3529	3.7	1
7	Unmasking Hydroxychloroquine Cardiotoxicity in a Patient With Heart Failure and Chronotropic Incompetence. <i>JACC: Case Reports</i> , 2021 , 3, 997-1001	1.2	0
6	Use of Hydroxychloroquine and Risk of Heart Failure in Patients With Rheumatoid Arthritis. <i>Journal of Rheumatology</i> , 2021 , 48, 1508-1511	4.1	0

5	Cardiovascular Risk of Synthetic, Non-Biologic Disease-Modifying Anti- Rheumatic Drugs (DMARDs). <i>Current Vascular Pharmacology</i> , 2020 , 18, 455-462	3.3	0
4	Expanding horizons for clinical applications of chloroquine, hydroxychloroquine, and related structural analogues. <i>Drugs in Context</i> , 2019 , 8,	5.2	25
3	Chloroquine and hydroxychloroquine in the context of COVID-19. <i>Drugs in Context</i> , 2020 , 9,	5.2	23
2	Cardiac Involvement: Evaluation and Management. 2017 , 331-356		
1	Restrictive cardiomyopathy.		0